^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression
    Cancer:Acute Promyelocytic Leukemia
    Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) +
    idarubicin hydrochloride (Topoisomerase II inhibitor, DNA cross linking agent) +
    arsenic trioxide (Apoptosis stimulant) +
    hydroxyurea (DNA synthesis inhibitor, Ribonucleotide reductase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Sao Paulo Med J
    Title:

    Acute WT1-positive promyelocytic leukemia with hypogranular variant morphology, bcr-3 isoform of PML-RARa and Flt3-ITD mutation: a rare case report

    Excerpt:
    Here, we describe a case of APL with high white blood cell counts in blood tests and hypogranular variant morphology in bone marrow, together with fms-like tyrosine kinase-3 with internal tandem duplication mutations (FLT3-ITD), and bcr-3 isoform of PML-RARα. Most importantly, we detected high level of Wilms' tumor gene (WT1) in marrow blasts... This patient successively received a combined treatment regimen consisting of hydroxycarbamide, arsenic trioxide and idarubicin plus cytarabine, which ultimately enabled complete remission.
    DOI:
    10.1590/1516-3180.2016.020104102016